V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240008108 | 240004985 | 1.76 | 91.5 | Palliative (P) | 2014-10-31 | 2014-11-20 | Methotrexate intrathecal | N | N | 240001110 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 240008109 | 240004985 | null | 53 | null | 2016-09-18 | 2016-09-18 | Carboplatin + Pemetrexed | N | null | 240001110 | ECX |
| 240008110 | 240004985 | 1.75 | 71.7 | Curative (C) | 2015-07-27 | 2015-07-27 | DA-EPOCH-R | N | N | 240001110 | CYCLO + RITUXIMAB + VINCRISTINE |
| 240008111 | 240004985 | 1.68 | 60 | Palliative (P) | 2018-10-24 | 2018-11-08 | PACE-BOM | N | N | 240001110 | CISPLATIN + ETOPOSIDE |
| 240008112 | 240004985 | 1.55 | 76.8 | Curative (C) | 2016-06-06 | 2016-06-07 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | 02 | N | 240001110 | BLEOMYCIN + CISPLATIN + MTOMYCIN |
| 240008113 | 240004985 | 1.84 | 98 | Disease modification (D) | null | 2014-09-13 | GDP | N | N | 240001110 | CYCLOPHOSPHAMIDE |
| 240008114 | 240004986 | null | 94.8 | Neo-adjuvant (N) | null | 2015-07-11 | VEDex | N | N | 240001328 | FLAG + IDARUBICIN |
| 240008115 | 240004986 | 1.65 | 72.6 | Curative (C) | 2018-03-01 | 2018-03-21 | Imatinib 400mg | 2 | N | 240001328 | FCR |
| 240008116 | 240004987 | 1.64 | 96 | Palliative (P) | 2016-12-29 | 2017-01-06 | PACLITAXEL | null | N | 240001338 | GEMCARBO |
| 240008117 | 240004988 | 1.61 | 67.1 | Palliative (P) | 2014-07-03 | 2014-07-07 | FLUDARABINE | 2 | N | 240001374 | CISPLATIN + ETOPOSIDE |
| 240008118 | 240010761 | null | 92 | null | 2017-09-25 | 2017-09-25 | Cisplatin + Etoposide (3 day) | N | N | 240001402 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008119 | 240013584 | 0 | 53.3 | Curative (C) | 2018-06-08 | 2018-06-21 | Bevacizumab 15mg/kg | 02 | N | 240001406 | MITOXANTRONE |
| 240008120 | 240013584 | 1.6 | 63.2 | Curative (C) | 2016-12-17 | 2016-12-21 | Cytarabine HD + Methotrexate HD | N | Y | 240001406 | ABVD R |
| 240008121 | 240004989 | 1.51 | 57 | Disease modification (D) | null | 2015-05-17 | CVP | Y | N | 240001451 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008122 | 240004990 | 1.65 | 53 | Not known (9) | 2014-05-17 | 2014-05-25 | CISPLATIN + FLUOROURACIL + RT | N | N | 240001453 | CHOP R + METHOTREXATE |
| 240008123 | 240004990 | 1.8 | null | Neo-adjuvant (N) | 2017-01-29 | 2017-01-30 | CVP | 02 | N | 240001453 | CVP R + GEMCITABINE |
| 240008124 | 240004991 | 1.72 | 68.5 | Palliative (P) | 2015-08-06 | 2015-08-20 | CHOEP - 14 days | N | N | 240001528 | ENZALUTAMIDE |
| 240008125 | 240004991 | 1.64 | 74.6 | Curative (C) | 2018-02-02 | 2018-03-08 | Cisplatin + Etoposide (3 day) | N | Y | 240001528 | IMATINIB |
| 240008126 | 240004991 | 1.74 | 57 | Palliative (P) | 2015-10-12 | 2015-10-14 | NORDIC | N | N | 240001528 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 240008127 | 240004991 | 1.76 | 60.8 | Not known (9) | 2016-07-18 | 2016-07-19 | AML 19 TRIAL | 2 | N | 240001528 | NORDIC |
| 240008128 | 240004991 | 1.62 | 70.4 | null | 2017-09-10 | 2017-09-13 | PACLITAXEL + TRASTUZUMAB | N | N | 240001528 | CISPLATIN + ETOPOSIDE |
| 240008129 | 240004992 | 1.81 | 62.8 | Neo-adjuvant (N) | null | 2014-11-24 | NORDIC | null | Y | 240001599 | CHOEP |
| 240008132 | 240004994 | 0 | null | Palliative (P) | 2018-05-13 | 2018-05-16 | Bortezomib + Cyclophos + Dex | 2 | N | 240001683 | TRIPLE INTRATHECAL |
| 240008133 | 240004994 | 1.69 | 75.6 | null | null | 2016-01-09 | RUXOLITINIB | null | null | 240001683 | RCEOP |
| 240008134 | 240004994 | 1.82 | 98.5 | Palliative (P) | null | 2018-11-30 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 240001683 | CLADRIBINE |
| 240008135 | 240014958 | 1.67 | 82.6 | Palliative (P) | 2015-07-07 | 2015-07-08 | IVE-R | 02 | Y | 240001806 | BEVACIZUMAB + CISPLATIN + PACLITAXEL |
| 240008136 | 240004995 | 1.5 | 64.9 | Disease modification (D) | 2018-05-13 | 2018-05-28 | Cytarabine intrathecal | N | N | 240001854 | mEOC TRIAL |
| 240008137 | 240004996 | 1.73 | null | Palliative (P) | 2018-02-23 | 2018-03-26 | Fludarabine oral | N | N | 240001941 | ABVD |
| 240008138 | 240004996 | null | 64.6 | Palliative (P) | 2015-02-07 | 2015-02-13 | CYCLOPHOSPHAMIDE | N | N | 240001941 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008139 | 240013587 | 1.55 | 82.7 | Disease modification (D) | 2014-07-19 | 2014-07-19 | POMALIDOMIDE | 1 | null | 240001948 | MITOXANTRONE |
| 240008140 | 240013587 | 0 | 73.9 | Palliative (P) | 2014-02-02 | 2014-02-21 | RUXOLITINIB | null | N | 240001948 | BEAM |
| 240008141 | 240013587 | 1.71 | 75 | Curative (C) | 2016-05-10 | 2016-05-10 | DA-EPOCH-R | 02 | N | 240001948 | CVP R + GEMCITABINE |
| 240008142 | 240004997 | 1.6 | null | Curative (C) | 2015-11-21 | 2015-11-22 | Cytarabine low (10to20mg/m2) IV/SC | 02 | null | 240002076 | DOXORUBICIN |
| 240008143 | 240004998 | 0 | null | Curative (C) | 2018-07-26 | 2018-08-02 | DA-EPOCH-R | 02 | N | 240002089 | ABVD |
| 240008144 | 240004999 | 0 | 63 | Adjuvant (A) | 2016-06-19 | 2016-08-13 | Cytarabine Low Dose | N | N | 240002098 | MPV |
| 240008145 | 240005000 | 1.72 | 68.4 | Palliative (P) | 2016-04-15 | 2016-04-18 | FLAG + Idarubicin | N | N | 240002099 | BEVACIZUMAB + CISPLATIN + PACLITAXEL |
| 240008146 | 240010767 | 1.75 | 102.2 | Palliative (P) | 2016-05-31 | 2016-06-19 | Cytarabine Low Dose | 2 | null | 240002201 | EOX |
| 240008147 | 240005001 | 1.74 | null | Curative (C) | 2016-04-14 | 2016-04-25 | FCR Oral - Cycle 1 | N | N | 240002216 | ABIRATERONE |
| 240008148 | 240005001 | 1.8 | 72.5 | Curative (C) | 2013-11-12 | 2013-11-21 | FLAG | 02 | N | 240002216 | GALLIUM TRIAL |
| 240008149 | 240013588 | 1.6 | 73.3 | Curative (C) | 2017-06-13 | 2017-06-19 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | N | N | 240002302 | MITOXANTRONE |
| 240008150 | 240013588 | 1.58 | 62 | Palliative (P) | null | 2016-03-20 | CARBOPLATIN + FLUOROURACIL | N | N | 240002302 | CHLVPP |
| 240008151 | 240015661 | null | null | Disease modification (D) | 2018-08-16 | 2018-08-23 | ABVD | 2 | N | 240002317 | LOMUSTINE |
| 240008152 | 240005002 | null | 73 | Palliative (P) | 2015-08-12 | 2015-08-26 | Abiraterone | 2 | null | 240002318 | GEMCITABINE + OXALIPLATIN |
| 240008153 | 240010769 | 1.68 | 43.6 | Adjuvant (A) | 2015-12-09 | 2015-12-11 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | 240002319 | CARBOPLATIN + TOPOTECAN |
| 240008154 | 240005003 | 1.73 | 71.7 | Curative (C) | 2017-10-10 | 2017-10-10 | Bevacizumab 15mg/kg | N | N | 240002326 | CAPECITABINE |
| 240008155 | 240005003 | 0 | 0 | Palliative (P) | 2017-12-11 | 2017-12-26 | Cyclophosphamide + Dex + Rituximab | N | N | 240002326 | CISPLATIN + ETOPOSIDE + RT |
| 240008156 | 240005004 | 1.54 | null | Adjuvant (A) | 2015-07-19 | 2015-07-19 | R CODOX M | 02 | N | 240002350 | CHOEP |
| 240008157 | 240010771 | 0 | null | Curative (C) | 2015-12-22 | 2015-12-27 | PMitCEBO-R | N | N | 240002351 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008158 | 240005005 | 1.69 | 67.2 | Curative (C) | 2015-05-11 | 2015-05-18 | ABVD | null | Y | 240002356 | CISPLATIN + ETOPOSIDE |
| 240008159 | 240005006 | null | 66.4 | Curative (C) | 2017-11-05 | 2017-11-12 | FCR Oral - Cycle 1 | N | N | 240002398 | CVP |